MedTrace Logo

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

NCT00748982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-06-27

Study results available
· View outcomes & findings →

Summary

To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction

Conditions

  • Left Ventricle Function

Interventions

DRUG

AZD1305

iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes

DRUG

Placebo

iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes

Sponsors & Collaborators

Principal Investigators

  • Helen Lund, MD · AstraZeneca R&D, Mölndal, Sweden

  • Marianne Hartford, MD · AstraZeneca, Clinical Pharmacology Unit at Sahlgrenska University Hospital, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00748982 on ClinicalTrials.gov